Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.83Venus Remedies Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company exhibits good solvency, driven by a strong equity position. Growth prospects appear promising, fueled by positive trends in operating profit, EPS, and asset expansion. Profitability, particularly regarding ROCE and ROA, is a notable strength. However, liquidity is a significant area of concern, reflecting challenges in meeting short-term obligations. Efficiency ratios also indicate potential operational bottlenecks. While coverage ratios are weak, the financial ratios present a moderate outlook, supported by cash EPS and book value per share. The company's future hinges on addressing its liquidity issues and improving operational efficiency to capitalize on its growth and profitability.
Health Score : 4.83Venus Remedies Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company exhibits good solvency, driven by a strong equity position. Growth prospects appear promising, fueled by positive trends in operating profit, EPS, and asset expansion. Profitability, particularly regarding ROCE and ROA, is a notable strength. However, liquidity is a significant area of concern, reflecting challenges in meeting short-term obligations. Efficiency ratios also indicate potential operational bottlenecks. While coverage ratios are weak, the financial ratios present a moderate outlook, supported by cash EPS and book value per share. The company's future hinges on addressing its liquidity issues and improving operational efficiency to capitalize on its growth and profitability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
24.19
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
23.37
P/B RATIO
3.62
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
N/A
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.00
EV/EBITDA RATIO
0.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1797.5 as on Jun 12, 2026.
Growth Score : 6.00The company exhibits strong growth in several key areas, including operating profit, EPS, and asset growth. However, the lack of revenue and net income growth suggests that these improvements are not translating into top-line performance. While profitability is increasing, the company needs to focus on driving revenue growth to achieve sustainable long-term expansion.
Revenue Growth RatePoor
Operating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 9.74 | -7.54 | 7.97 | 7.38 | 20.31 |
| Operating Profit Growth Rate | 14.81 | -3.23 | 0 | 6.67 | 129.69 |
| Earnings Per Share (EPS) Growth | -39.14 | -34.73 | 7.19 | 59.08 | 126.84 |
| Asset Growth Rate | 4.32 | 3.62 | 4.33 | 14.19 | 19.27 |
| Net Income Growth Rate | -33.87 | -34.15 | 3.7 | 60.71 | 128.89 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 3 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 4 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 5 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 6 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 7 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 8 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 9 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 10 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 13 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 14 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 15 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 16 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 17 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 18 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 19 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 20 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Venus Remedies Ltd is an India-based pharmaceutical company focused on research and development, manufacturing, and marketing of critical care and oncology products. Specializing in anti-infectives, oncology, pain management, and neurosciences, the company has a significant presence in both domestic and international markets, holding various international quality accreditations for its facilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Venus Remedies Ltd's P/E ratio (TTM) is 24.19, compared to the industry median of 23.93 and large cap median of 23.93.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Venus Remedies Ltd's P/B ratio is 3.62, compared to the industry median of 2.53 and large cap median of 2.53.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Venus Remedies Ltd's P/S ratio is 1.22, compared to the industry median of 1.35 and large cap median of 1.35.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Venus Remedies Ltd's PEG ratio is 1.20.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Venus Remedies Ltd's EV/EBITDA ratio is 10.50.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Venus Remedies Ltd's ROE is 15.54%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Venus Remedies Ltd's ROA is 17.21%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Venus Remedies Ltd's ROCE is 22%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Venus Remedies Ltd's operating margin is 19.09%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Venus Remedies Ltd's net margin is 13.38%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Venus Remedies Ltd's current ratio is 1.87.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Venus Remedies Ltd's debt-to-equity ratio is 0.02.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Venus Remedies Ltd's interest coverage ratio is N/A.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Venus Remedies Ltd's DPS is ₹10.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Venus Remedies Ltd's EPS is 126.84.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1797.50. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1991
Headquarters: Panchkula, Haryana
Core Offerings: Anti-infectives, Oncology, Pain Management, Neurosciences, Critical Care drugs
Stock Listing: NSE (VENUSREM), BSE (526953)
Promoter: Chaudhry Group (Pawan Chaudhary)
Venus Remedies Ltd was incorporated in 1991, establishing itself as a pharmaceutical manufacturer. Over the years, the company expanded its focus to include extensive research and development, particularly in critical care segments like anti-infectives and oncology. It has achieved various international accreditations such as WHO-GMP and EU-GMP, enabling a strong export footprint to over 70 countries. The company continues to innovate and strengthen its product portfolio in key therapeutic areas.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Products | 100% | Operating Profit |
Mr. Pawan Chaudhary - Chairman & Managing Director. A visionary leader who has steered Venus Remedies since its inception, driving its growth from a pharmaceutical manufacturer to a research-driven global player. Ms. Sarika Chaudhary - Joint Managing Director. Contributes significantly to the strategic management and operational efficiency of the company.
Venus Pharma GmbH (Germany)
Venus Pharma Inc (USA)
Venus Medicine Research Centre
No major recent corporate actions on record.
The Venus Remedies Ltd share price today is ₹1797.50 on NSE (VENUSREM), as of 26 Sept 2026.
As of 25 Sept 2026, Venus Remedies Ltd share price is ₹1797.50, with previous close ₹1797.50. Today's range is ₹1797.50 to ₹1797.50. The 52-week range is ₹622.10 to ₹2044.30.
As of today, Venus Remedies Ltd's market cap is ₹0 crore (Small Cap).
Venus Remedies Ltd's current P/E ratio is 24.19, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.
Venus Remedies Ltd's current P/B ratio is 3.62.
Venus Remedies Ltd's current dividend yield is 0.56%. Last dividend of ₹3.00 per share was declared on 14-Sep-2023.
Venus Remedies Ltd's EPS (TTM) is ₹126.84.
Venus Remedies Ltd is an India-based pharmaceutical company focused on research and development, manufacturing, and marketing of critical care and oncology products. Specializing in anti-infectives, oncology, pain management, and neurosciences, the company has a significant presence in both domestic and international markets, holding various international quality accreditations for its facilities.
Venus Remedies Ltd is promoted by Chaudhry Group (Pawan Chaudhary), holding 41.76% as of 25 Sept 2026.
Venus Remedies Ltd is listed on NSE (VENUSREM) and BSE (526953). Its next quarterly results are expected on August 2024 (Q1 FY25).
Return on Assets (ROA)
